Dr. Kumar Discusses Ixazomib in Multiple Myeloma

Shaji K. Kumar, MD
Published: Wednesday, Jul 05, 2017



Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

The proteasome inhibitor ixazomib is being evaluated in combination with lenalidomide (Revlimid) and dexamethasone in patients with newly diagnosed multiple myeloma.
 
SELECTED
LANGUAGE


Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

The proteasome inhibitor ixazomib is being evaluated in combination with lenalidomide (Revlimid) and dexamethasone in patients with newly diagnosed multiple myeloma.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x